Category Specific RSS

News

Webcentral enters agreement to partially sell its domains business at mammoth valuation

Digital services company Webcentral (ASX: WCG) has pulled off a substantial M&A coup having secured an agreement to sell two-thirds…

3 years ago

Algorae Pharmaceuticals collaborates with UNSW for AI biopharmaceutical prediction platform for dementia and heart diseases

As of 2023, over 400,000 Australians live with dementia, with over a million people assigned to their care. It is…

3 years ago

G8 sells off 31 underperforming childcare centres to Genius Education for reallocation of resources

Early education provider G8 Education (ASX: GEM) has signed a conditional agreement to sell 31 centres to TAK Operations, part…

3 years ago

Mad Paws inches closer towards cash flow positivity as Aussies won’t hold back on pet care spending

With one of the world's highest pet ownership rates at 69%, Australia's 2022 national pet survey reveals Aussies spare no…

3 years ago

Dumb Ways to Die: the viral audio that perked up PlaySide’s revenue

You’ve probably heard the Dumb Ways to Die audio while scrolling on Instagram or TikTok, but did you know where…

3 years ago

Harris Technology to expand private label tech products into Australia in time for retail season

As consumers around the world face inflationary pressures, there has been a rising trend towards low-cost alternative tech products, a…

3 years ago

Reduced household budgets hurt Cluey’s revenue, cost-cutting measures introduced

Even after its cost-cutting initiatives proved helpful, tutoring firm Cluey (ASX: CLU) has been dealing with setbacks in the face…

3 years ago

After selling US arm to focus on Australia, PointsBet gets the winning ball rolling

While most companies create grand plans to enter the US, online wagering company PointsBet (ASX: PBH) is glad to wash…

3 years ago

IncentiaPay rejects takeover offer, cites undervaluation and uncertainty

Loyalty pays. Just ask IncentiaPay (ASX: INP) which has firmly rejected an unsolicited takeover proposal from a Melbourne-based loyalty and…

3 years ago

Syntara accelerates clinical trials and blood cancer drug pipeline following mannitol business sale

Syntara - it’s a name that biotech investors will be hearing a lot in the years to come with the…

3 years ago